Filing Flows › Comparisons › FATE vs SCTX
Fate Therapeutics vs Scribe Therapeutics: FATE and SCTX compared
Fate Therapeutics is the larger company: $2.1M of revenue in its latest quarter (Q2 2026) against $1.9M for Scribe Therapeutics (Q2 2026). Fate Therapeutics is growing faster (+9% against -61% a year earlier).
Where the money goes: FATE and SCTX
Fate Therapeutics (FATE) · Q2 2026
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
Scribe Therapeutics (SCTX) · Q2 2026
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart follows the revenue to costs, profit and cash.
| Fate Therapeutics (FATE) | Scribe Therapeutics (SCTX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $2.1M | $1.9M |
| Revenue growth, Y/Y | +9% | -61% |
| Operating margin | n/m | -489.8% |
| Net earnings | −$30.2M | −$6.5M |
| Net margin | — | -337.7% |
| Operating cash flow | −$23.4M | — |
Questions
Which is bigger, Fate Therapeutics or Scribe Therapeutics?
Fate Therapeutics is the larger company: $2.1M of revenue in its latest quarter (Q2 2026) against $1.9M for Scribe Therapeutics (Q2 2026).
Is Fate Therapeutics or Scribe Therapeutics growing faster?
Fate Therapeutics is growing faster (+9% against -61% a year earlier).
More: Fate Therapeutics earnings · how Fate Therapeutics makes money · Scribe Therapeutics earnings · how Scribe Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Sep 2, 2026). Fiscal quarters can end on different dates. Not investment advice.